Sildenafil may benefit children with pulmonary arterial hypertension

October 24, 2011, American College of Chest Physicians

Sildenafil is currently approved for adult pulmonary arterial hypertension (PAH); however, new research presented at CHEST 2011, the 77th annual meeting of the American College of Chest Physicians (ACCP), shows the drug may also provide significant benefits for children with PAH, helping to improve both oxygen delivery and exercise capacity.

" is a , and it is even more rare in . But the disease is horrific, with the less than one year in children if untreated; however, with appropriate treatment, 5¬year survival should be over 80 percent," said study author Robyn Barst, MD, FCCP, Columbia University, New York, NY. "This is a landmark study – the first, and to date, the only study that has adequately evaluated a drug for the treatment of PAH in children." PAH, characterized by narrowing of the small arteries that carry blood from the heart to the lungs, leads to shortness of breath, chest pain, swelling in the lower body, fatigue, and heart failure.

Not only is PAH rare in children, it is also difficult to diagnose and treat. "Diagnosis from onset of symptoms is often 2 years or more because patients often have nondescript symptoms such as breathlessness with exercise and fatigue," said Dr. Barst. "If PAH is not suspected, the appropriate tests will not be performed until the disease has progressed, often to the point the patient has fainting episodes or heart failure." Once PAH is diagnosed, managing the condition in children brings new challenges. Although the disease is similar in children and adults, optimal treatment is not necessarily the same.

"Children are not just 'small adults.' Before prescribing drugs for children, we need to know if the drug works, what dose should we use, is the drug well tolerated, what side effects the drug has, and is it safe in the short term and long term" said Dr. Barst. "In addition, adequate clinical studies are needed to provide evidence-based treatment guidelines for children with PAH."

To address this issue, Dr. Barst and colleagues conducted a randomized, double-blind study involving 32 medical centers in 16 countries, to assess the outcomes of sildenafil therapy in 234 children (aged 1-17 years) with PAH, as they received low, medium, or high-dose sildenafil, or placebo for 16 weeks. Cardiopulmonary exercise testing, peak oxygen consumption (pVO2), and minute ventilation to carbon dioxide output (VE/VCO2) levels were determined at baseline and at week 16 in all children who could reliably exercise on a bicycle (n=106). Although the primary endpoint of % change in pVO2 did not meet predefined criteria (p = 0.056), children receiving sildenafil therapy at medium and high dose had greater improvements in pVO2 and VE/VCO2 slope (ie, the relationship between the two variables) vs placebo, signifying an improvement in both and blood flow through the lungs. Sildenafil also increased the amount of exercise the children could perform and made it easier for them to exercise. In addition, sildenafil improved the gas exchange efficiency of the lungs during exercise. Outcomes appeared better for patients with idiopathic/heritable PAH vs congenital heart defect-associated PAH. Long-term follow-up of these patients three years after the initial trial revealed a concern for increased mortality in the high dose group, suggesting that the medium dose may have the best risk-benefit ratio.

Although sildenafil is not yet approved for use in pediatric patients with PAH, this study is the first step to evaluate the safety and effectiveness of treatments for children. "The goal in treating the children is to improve their overall quality of life, in addition to hopefully improving their survival," said Dr. Barst. "We want to make the children feel better and not just live longer. Thus, a thorough evaluation is difficult, but it is critically important."

"Historically, PAH has been difficult to manage; however, treatments have been advancing rapidly," said David Gutterman, MD, FCCP, President of the . "Continued research and well-controlled clinical trials should lead to further improvements in the treatment of this very challenging disease."

Explore further: Heart drugs ineffective in treating pulmonary arterial hypertension

Related Stories

Heart drugs ineffective in treating pulmonary arterial hypertension

May 18, 2011
Despite their beneficial effects in treating heart disease, neither aspirin nor simvastatin appear to offer benefit to patients suffering from pulmonary artery hypertension (PAH), according to a National Institutes of Health ...

Women with pulmonary arterial hypertension have greater response to treatment than men

September 28, 2011
Pulmonary arterial hypertension (PAH) patients of different sexes and races may respond differently to treatment with commonly used medications for the disease, says a new study from researchers at Perelman School of Medicine ...

New study may lead to quicker diagnosis, improved treatment for fatal lung disease

July 11, 2011
One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers ...

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.